Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Cancer Commun (Lond). 2024 Jan;44(1):3-22. doi: 10.1002/cac2.12517. Epub 2023 Dec 30.
In recent years, remarkable breakthroughs have been reported on antibody-drug conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade. This substantial development has positioned ADCs as one of the fastest-growing domains in the realm of anticancer drugs, demonstrating their efficacy in treating a wide array of malignancies. Nonetheless, there is still an unmet clinical need for wider application, better efficacy, and fewer side effects of ADCs. An ADC generally comprises an antibody, a linker and a payload, and the combination has profound effects on drug structure, pharmacokinetic profile and efficacy. Hence, optimization of the key components provides an opportunity to develop ADCs with higher potency and fewer side effects. In this review, we comprehensively reviewed the current development and the prospects of ADC, provided an analysis of marketed ADCs and the ongoing pipelines globally as well as in China, highlighted several ADC platforms and technologies specific to different pharmaceutical enterprises and biotech companies, and also discussed the new related technologies, possibility of next-generation ADCs and the directions of clinical research.
近年来，抗体药物偶联物（ADC）取得了显著的突破，在过去十年中已有 15 种 ADC 成功上市。这种实质性的发展使 ADC 成为抗癌药物中增长最快的领域之一，证明了它们在治疗多种恶性肿瘤方面的疗效。然而，ADC 的广泛应用、更好的疗效和更少的副作用仍存在未满足的临床需求。ADC 通常由抗体、连接子和有效载荷组成，这种组合对药物结构、药代动力学特征和疗效有深远的影响。因此，优化关键组件为开发具有更高效力和更少副作用的 ADC 提供了机会。在这篇综述中，我们全面回顾了 ADC 的现状和前景，分析了全球和中国已上市的 ADC 以及正在进行的管线，强调了几家制药企业和生物技术公司特有的几种 ADC 平台和技术，并讨论了新的相关技术、下一代 ADC 的可能性以及临床研究的方向。
